세계의 의약품 허브 및 환자 액세스 지원 서비스 시장 - 규모, 점유율, 동향 분석 보고서 : 서비스 유형별, 서비스 제공 유형별, 지역별 부문 예측(2024-2030년)

Pharma HUB And Patient Access Support Service Market Growth & Trends:

The global pharma HUB and patient access support service market size is expected to reach USD 5.7 billion by 2030, registering a CAGR of 9.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the significant prevalence of rare and orphan-diseased patients requiring access to specific medicines. Furthermore, the market is driven by an emphasis on establishing a patient-centered ecosystem to provide extensive support to patients throughout their treatment and an increasing demand for tailored solutions aimed at improving patient outcomes.

The prevalence of rare diseases has fueled growth in the pharmaceutical hub and patient access support service market. It is driven by specialized treatment demand, incentives for orphan drug development, the need for patient access support due to rarity, global collaborative efforts, and an expanding market for rare disease treatments. These factors have led to increased investment, innovation, and collaboration in the pharmaceutical industry, particularly in areas related to rare disease research, development, and patient support services.

Up to 36 million people in the EU are affected by rare diseases, which encompass over 6,000 distinct conditions. While some rare diseases impact only a few patients, others can affect as many as 245,000 individuals. About 80% of these diseases have genetic roots, with 70% beginning in childhood. Furthermore, in the U.S., over 10,000 rare diseases impact more than 30 million people. Moreover, it's estimated that 6-8% of the population in India is affected by rare or ultra-rare diseases. Hence, the significant prevalence of rare diseases is expected to contribute to the market growth.

Pharmaceutical companies are prioritizing the needs of patients by creating a patient-centric ecosystem that offers services to support them throughout their therapy journey. This is due to various factors such as lack of proper training, medication non-adherence, and fear of adverse effects, or missed appointments, which can affect a patient's treatment. Patients can access relevant patient service resources and start engaging with the organization as soon as they are prescribed a particular therapy.

With advanced analytics and AI technology, patient services teams can now obtain actionable insights to cater to each patient's individual needs as they progress through their treatment journey. This tailored approach ensures that patients receive the right support at the right time, leading to better therapy outcomes. For instance, companies such as Managed Markets Insight & Technology, LLC, IQVIA, & IntegriChain are offering such solutions in order to overcome barriers to patient access.

Furthermore, the life sciences industry is adapting to the digital era by focusing on value-based care and outcome-driven models that prioritize integrated services. This shift has led to the adoption of technological advancements in integrated solutions to enhance patient access and improve healthcare outcomes. One such example is the PatientLink platform, a new enterprise SaaS by TrialCard. Launched in April 2022, PatientLink simplifies patient access and engagement with Patient Support Programs while improving adherence to medication. It is a highly configurable service that offers an omnichannel experience, enabling leaders in life sciences to meet the needs of a demanding healthcare marketplace through multi-system interoperability.

Pharma HUB And Patient Access Support Service Market Report Highlights:

• Based on service type, the program enrollment segment held the largest market share in 2023. Its growth can be attributed to growing demand for customized solutions and the increasing need to improve patient outcomes drive
• Based on service delivery type, the integrated services segment held the largest market share in 2023. Its dominance is because the integrated solutions offer a unified platform to manage various functions such as patient access support, reimbursement assistance, and pharmacy coordination
• North America dominated the global market with the largest revenue share in 2023. Its growth can be attributed to the rising prevalence of lifestyle-associated diseases, such as diabetes & cardiovascular disorders, growing number of clinical trial-based research, strong presence of market players in the region, and presence of developed countries, such as the U.S.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Service Type
  • 1.1.2. Service Delivery Type
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service type outlook
  • 2.2.2. Service delivery type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharma HUB And Patient Access Support Service Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharma HUB And Patient Access Support Service Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & legal landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social & environmental landscape
    • 3.3.2.4. Technological landscape
  • 3.3.3. Impact of COVID-19

Chapter 4. Pharma HUB And Patient Access Support Service Market: Service Type Estimates & Trend Analysis

• 4.1. Service Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Pharma HUB And Patient Access Support Service Market by Service Type Outlook
• 4.4. Program Enrollment
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.2. Order processing
    • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.3. Application processing
    • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
    • 4.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.5. Program data
    • 4.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Treatment Navigators
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Process flows and standard operating procedures
    • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Program literature and scripts
    • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.4. Care team training
    • 4.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.5. Systems testing and optimization
    • 4.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Reimbursement Services/Affordability Services
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Clinical Educator
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.8. Coordination of Specialty Pharmacy/Dispensing
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Pharma HUB And Patient Access Support Service Market: Service Delivery Type Estimates & Trend Analysis

• 5.1. Service Delivery Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Pharma HUB And Patient Access Support Service Market by Service Delivery Type Outlook
• 5.4. Integrated Services
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Standalone Services
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Pharma HUB And Patient Access Support Service Market: Regional Estimates & Trend Analysis, By Service Type, By Service Delivery Type

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Denmark
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Norway
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
  • 7.2.2. List of key distributors and channel partners
  • 7.2.3. Key customers
  • 7.2.4. Key company market share analysis, 2023
  • 7.2.5. PharmaCord
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Fortrea
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. AssistRx
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. CareMetx
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. ConnectiveRx
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Lash Group
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. McKesson
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Inizio Engage
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. Sonexus Health (acquired by Cardinal Health)
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives
  • 7.2.15. Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
    • 7.2.15.1. Company overview
    • 7.2.15.2. Financial performance
    • 7.2.15.3. Product benchmarking
    • 7.2.15.4. Strategic initiatives
  • 7.2.16. EVERSANA
    • 7.2.16.1. Company overview
    • 7.2.16.2. Financial performance
    • 7.2.16.3. Product benchmarking
    • 7.2.16.4. Strategic initiatives
  • 7.2.17. United BioSource LLC (UBC)
    • 7.2.17.1. Company overview
    • 7.2.17.2. Financial performance
    • 7.2.17.3. Product benchmarking
    • 7.2.17.4. Strategic initiatives
  • 7.2.18. Mercalis
    • 7.2.18.1. Company overview
    • 7.2.18.2. Financial performance
    • 7.2.18.3. Product benchmarking
    • 7.2.18.4. Strategic initiatives